Global Health (MEDANTA) Fundamentals 2026 — P/E 65.4x, Revenue Analysis | SniperIQ
Global Health (MEDANTA) is a India-listed Healthcare company in Medical - Care Facilities with a market capitalization of ₹36,675 Crore, trading at ₹1353.75 on the BSE. This SniperIQ fundamentals page covers Global Health's valuation (P/E 65.4x, P/B 9.2x), profitability (net margin 12.6%), revenue (₹4,410 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Global Health's market cap?
Global Health (MEDANTA) has a market capitalization of approximately ₹36,675 Crore, trading at ₹1353.75 on the BSE. Market cap moves with the live share price.
What is Global Health's P/E ratio?
Global Health's trailing twelve-month P/E ratio is 65.4x, with a price-to-book (P/B) of 9.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Global Health?
Global Health runs a net profit margin of 12.6%, a gross margin of 69.4%, and an operating margin of 15.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Global Health generate?
Global Health reported revenue of ₹4,410 Crore for fiscal year 2026, with net income of ₹556 Crore and earnings per share (EPS) of 20.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Global Health pay a dividend?
Global Health offers a trailing dividend yield of about 0.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Global Health financially healthy?
Global Health carries a debt-to-equity ratio of 0.30x and a current ratio of 2.67x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Global Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Global Health (MEDANTA) the key facts are: market cap ₹36,675 Crore, P/E 65.4x, revenue ₹4,410 Crore, 52-week range 955.2-1455.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Global Health's full fundamentals live
Get Global Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.